ALX Oncology (ALXO) News Today → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free ALXO Stock Alerts $15.56 +0.39 (+2.57%) (As of 12:03 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 1:07 PM | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decline in Short InterestALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) was the recipient of a large decline in short interest in April. As of April 30th, there was short interest totalling 3,160,000 shares, a decline of 14.4% from the April 15th total of 3,690,000 shares. Based on an average daily volume of 521,400 shares, the days-to-cover ratio is currently 6.1 days. Approximately 11.5% of the shares of the company are short sold.May 12 at 1:14 AM | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)May 10, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...May 10, 2024 | americanbankingnews.comJaume Pons Sells 20,000 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) StockMay 10, 2024 | investorplace.comALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024May 9, 2024 | globenewswire.comALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $318,400.00 in StockMay 7, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Up 6.8%ALX Oncology (NASDAQ:ALXO) Shares Up 6.8%May 7, 2024 | globenewswire.comALX Oncology Appoints Allison Dillon as Chief Business OfficerMay 3, 2024 | msn.comRelay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09MApril 30, 2024 | finance.yahoo.comALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerApril 30, 2024 | marketbeat.com66,211 Shares in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Bought by abrdn plcabrdn plc bought a new position in ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 66,211 shares of the company's stock, valued at approximately $986,000. abrdn plc owned aboutApril 29, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Hits New 52-Week High at $17.45ALX Oncology (NASDAQ:ALXO) Sets New 52-Week High at $17.45April 28, 2024 | marketbeat.comFederated Hermes Inc. Sells 54,824 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)Federated Hermes Inc. decreased its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 21.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 196,536 shares of the company's stock after selling 54,824 shares duApril 24, 2024 | globenewswire.comALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 23, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Up 9.1%ALX Oncology (NASDAQ:ALXO) Trading 9.1% HigherApril 22, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Shares Down 4.8% ALX Oncology (NASDAQ:ALXO) Stock Price Down 4.8%April 20, 2024 | investing.comAlx Oncology's president & CSO sells $710k in stockApril 19, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $710,000.00 in StockApril 18, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 50,000 SharesALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Jaume Pons sold 50,000 shares of the stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now directly owns 604,205 shares of the company's stock, valued at $8,579,711. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.April 18, 2024 | seekingalpha.comALX Oncology: Trying To Justify The HypeApril 18, 2024 | seekingalpha.comENPH, OCUL and ITCI are among after hour moversApril 17, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Up 6.5%ALX Oncology (NASDAQ:ALXO) Shares Up 6.5%April 16, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Sees Large Volume IncreaseALX Oncology (NASDAQ:ALXO) Sees Large Volume IncreaseApril 13, 2024 | uk.investing.comALX Oncology hold rating reiterated with steady stock target by StifelApril 12, 2024 | marketbeat.comALX Oncology's (ALXO) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research report on Friday.April 11, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading 4.2% Higher ALX Oncology (NASDAQ:ALXO) Stock Price Up 4.2%April 11, 2024 | markets.businessinsider.comBuy Rating on ALX Oncology Holdings Amid Strong Clinical Data and Favorable rNPV AnalysisApril 10, 2024 | marketbeat.comALX Oncology's (ALXO) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of ALX Oncology in a research report on Wednesday.April 9, 2024 | globenewswire.comALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)April 8, 2024 | markets.businessinsider.comBuy Rating Justified by Promising Evorpacept Trial Results and Market PotentialApril 6, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 20,000 SharesApril 6, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Insider Sells SharesApril 4, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Up 3.6%ALX Oncology (NASDAQ:ALXO) Trading Up 3.6%March 27, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Shares Gap Up to $11.19ALX Oncology (NASDAQ:ALXO) Shares Gap Up to $11.19March 26, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Shares Down 3.6% ALX Oncology (NASDAQ:ALXO) Shares Down 3.6%March 20, 2024 | investing.comAlx Oncology CEO buys $49.7k in company sharesMarch 19, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Shares Gap Up Following Insider Buying ActivityALX Oncology (NASDAQ:ALXO) Shares Gap Up on Insider Buying ActivityMarch 19, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann Acquires 4,400 SharesMarch 18, 2024 | marketbeat.comALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann Buys 4,400 SharesALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann purchased 4,400 shares of the company's stock in a transaction dated Thursday, March 14th. The stock was acquired at an average price of $11.31 per share, with a total value of $49,764.00. Following the completion of the transaction, the chief executive officer now owns 171,620 shares of the company's stock, valued at approximately $1,941,022.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.March 17, 2024 | finance.yahoo.comALXO Apr 2024 7.000 putMarch 16, 2024 | finance.yahoo.comALXO Apr 2024 19.000 callMarch 16, 2024 | finance.yahoo.comALXO Apr 2024 14.000 putMarch 14, 2024 | marketbeat.comQ1 2024 Earnings Forecast for ALX Oncology Holdings Inc. Issued By HC Wainwright (NASDAQ:ALXO)ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Equities researchers at HC Wainwright increased their Q1 2024 earnings per share estimates for shares of ALX Oncology in a report released on Monday, March 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($March 11, 2024 | marketbeat.comALX Oncology (NASDAQ:ALXO) Trading Down 4%ALX Oncology (NASDAQ:ALXO) Stock Price Down 4%March 8, 2024 | markets.businessinsider.comALX Oncology’s Evorpacept Shows Promising Potential in Cancer Treatment StudiesMarch 8, 2024 | markets.businessinsider.comALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric CancerMarch 8, 2024 | realmoney.thestreet.comALX Oncology just downgraded at Stifel, here's whyMarch 8, 2024 | marketbeat.comStifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) to HoldStifel Nicolaus downgraded ALX Oncology from a "buy" rating to a "hold" rating and lifted their price target for the company from $10.00 to $14.00 in a research report on Friday. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. ALXO Media Mentions By Week ALXO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALXO News Sentiment▼0.840.56▲Average Medical News Sentiment ALXO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALXO Articles This Week▼132▲ALXO Articles Average Week Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Longboard Pharmaceuticals News Today Disc Medicine News Today Praxis Precision Medicines News Today Evolus News Today Arcturus Therapeutics News Today Tango Therapeutics News Today Dianthus Therapeutics News Today Zentalis Pharmaceuticals News Today PureTech Health News Today Aurinia Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALXO) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
